1,769 Shares in McKesson Corporation $MCK Purchased by Pacific Excel Wealth Advisors Inc.

Pacific Excel Wealth Advisors Inc. acquired a new position in shares of McKesson Corporation (NYSE:MCK) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 1,769 shares of the company’s stock, valued at approximately $1,337,000.

A number of other large investors also recently added to or reduced their stakes in MCK. Norges Bank acquired a new stake in shares of McKesson during the 4th quarter worth approximately $1,651,137,000. Swedbank AB lifted its holdings in McKesson by 42.2% in the fourth quarter. Swedbank AB now owns 886,283 shares of the company’s stock valued at $727,009,000 after buying an additional 263,189 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in McKesson by 4,300.3% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 214,693 shares of the company’s stock valued at $185,787,000 after buying an additional 209,814 shares during the period. SurgoCap Partners LP boosted its stake in McKesson by 68.7% in the third quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock valued at $349,390,000 after acquiring an additional 184,106 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its stake in McKesson by 73.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 432,578 shares of the company’s stock valued at $354,839,000 after acquiring an additional 183,590 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson Price Performance

NYSE MCK opened at $831.86 on Wednesday. McKesson Corporation has a one year low of $637.00 and a one year high of $999.00. The firm has a market cap of $97.39 billion, a P/E ratio of 21.62, a P/E/G ratio of 1.36 and a beta of 0.30. The stock’s 50-day moving average is $793.42 and its 200-day moving average is $840.32.

McKesson (NYSE:MCK) last posted its earnings results on Thursday, May 7th. The company reported $11.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The business had revenue of $96.30 billion during the quarter, compared to analysts’ expectations of $101.35 billion. During the same period in the prior year, the business earned $10.12 EPS. McKesson’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Equities analysts anticipate that McKesson Corporation will post 44.28 EPS for the current year.

McKesson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $3.76 annualized dividend and a yield of 0.5%. This is an increase from McKesson’s previous quarterly dividend of $0.82. McKesson’s payout ratio is presently 8.53%.

Insider Activity at McKesson

In related news, CEO Brian S. Tyler sold 8,463 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the completion of the transaction, the chief executive officer directly owned 5,919 shares in the company, valued at approximately $4,697,081.64. This trade represents a 58.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michele Lau sold 3,550 shares of McKesson stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total value of $2,701,869.50. Following the completion of the sale, the executive vice president directly owned 3,247 shares in the company, valued at approximately $2,471,259.23. This represents a 52.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 28,748 shares of company stock valued at $22,262,035 in the last quarter. 0.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on MCK. Wells Fargo & Company dropped their target price on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. William Blair initiated coverage on McKesson in a research report on Tuesday, April 28th. They issued an “outperform” rating on the stock. UBS Group upped their price objective on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Friday, May 8th. Citigroup increased their target price on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Finally, Barclays reduced their target price on McKesson from $1,050.00 to $925.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $962.67.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson is being highlighted as a potentially attractive long-term value stock. Supportive factors include its defensive pharmaceutical-distribution business, continued demand for specialty medicines and analyst price targets generally above the current trading range. Why McKesson Is a Top Value Stock for the Long Term
• Positive Sentiment: The earnings preview points to AI-driven operating efficiencies, specialty-pharmacy momentum and oncology growth as potential catalysts for the quarter. McKesson’s prior report also showed EPS above consensus and year-over-year revenue growth, reinforcing expectations for resilient profitability. Can AI-Driven Efficiency and Specialty Demand Boost MCK’s Q1 Results?
• Neutral Sentiment: Shares have been volatile ahead of the earnings release as investors weigh the company’s strong earnings performance against earlier revenue-miss concerns. The report could therefore become the next major catalyst for the stock.
• Neutral Sentiment: McKesson recently laid off dozens of employees at Rx Savings Solutions as part of a restructuring effort. The move could lower costs and improve efficiency, but it also highlights ongoing efforts to streamline operations. McKesson Lays Off Dozens at Rx Savings Solutions Amid Restructuring
• Negative Sentiment: Key risks ahead of the report include pharmaceutical pricing dynamics, tariffs and funding pressure across healthcare markets, which could restrain revenue growth even if demand remains solid. What’s in Store for These Healthcare Companies This Earnings Season?
• Negative Sentiment: Reported insider activity has been weighted toward sales, with no purchases cited during the past six months. While insider sales may reflect routine compensation or diversification, the pattern can add to pre-earnings investor caution.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.